ACTG174, 1994.

Study characteristics
Methods	Single arm trial
Participants	49 people with PDH according to the revised protocol
Interventions	Induction: FCN 1200 mg on first day, then 600 mg OD for 8 weeks Maintenance: FCN 200 mg OD for ≥ 1 year Following revision of protocol due to high failure rate (10/20) Induction: FCN 1600 mg on first day, then 800 mg OD for 12 weeks Maintenance: 400 mg OD for 1 year
Outcomes	"Treatment response" Induction: 36/49 (73.5%) participants responded at 12 weeks; 28 of these had resolution of signs/symptoms and negative cultures; 8 had clinical response but cultures missing/not done 7/49 failed treatment: 1 died histoplasmosis and pneumocystis around day 3 Maintenance: 11/36 participants relapsed. Median time on maintenance was 30 weeks. 10/11 had blood cultures, 8/10 were positive 1/36 participants withdrew due to drug toxicity
Age	Mean 36 (range not stated) years
Setting	USA
Disease severity	Mild to moderate
Notes	Study terminated early due to relatively high relapse rate (compared to earlier ITRA trial)